PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis

AS Murad; SJ Lewis; G Davey Smith; SM Collin; Chen L; Hamdy FC; Neal DE; JL Donovan; RM Martin

doi:10.1038/pcan.2009.18

PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis

AS Murad, SJ Lewis, G Davey Smith, SM Collin, Chen L, Hamdy FC, Neal DE, JL Donovan, RM Martin

Research output: Contribution to journal › Article (Academic Journal) › peer-review

18 Citations (Scopus)

Abstract

Prostaglandin endoperoxidase synthase 2 is a key regulator of inflammation and may play a role in prostate carcinogenesis. The polymorphism, -899G>C (rs20417), alters a transcription factor-binding site and is associated with a reduced risk of colorectal adenoma. We tested the hypothesis that rs20417 may influence prostate cancer risk, using a large case-control study (n(cases)=1608, n(controls)=3058). We found no evidence that rs20417 alters prostate cancer risk (odds ratio (OR(CC & GC v GG)=1.05, 95% confidence interval (CI)=0.91-1.20). A meta-analysis of three studies also found little evidence that rs20417 alters risk (pooled OR(CC & GC v GG)=1.04, 95% CI=0.93-1.17), making it unlikely that rs20417 contributes in any major way to prostate cancer aetiology.

Translated title of the contribution	PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis
Original language	English
Pages (from-to)	296 - 300
Number of pages	4
Journal	Prostate Cancer & Prostatic Diseases
Volume	12
DOIs	https://doi.org/10.1038/pcan.2009.18
Publication status	Published - Sept 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/pcan.2009.18

Handle.net

Persistent link

Cite this

@article{942ce2053c484662976ffffd1831a9e2,

title = "PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis",

abstract = "Prostaglandin endoperoxidase synthase 2 is a key regulator of inflammation and may play a role in prostate carcinogenesis. The polymorphism, -899G>C (rs20417), alters a transcription factor-binding site and is associated with a reduced risk of colorectal adenoma. We tested the hypothesis that rs20417 may influence prostate cancer risk, using a large case-control study (n(cases)=1608, n(controls)=3058). We found no evidence that rs20417 alters prostate cancer risk (odds ratio (OR(CC & GC v GG)=1.05, 95% confidence interval (CI)=0.91-1.20). A meta-analysis of three studies also found little evidence that rs20417 alters risk (pooled OR(CC & GC v GG)=1.04, 95% CI=0.93-1.17), making it unlikely that rs20417 contributes in any major way to prostate cancer aetiology.",

author = "AS Murad and SJ Lewis and {Davey Smith}, G and SM Collin and Chen L and Hamdy FC and Neal DE and JL Donovan and RM Martin",

year = "2009",

month = sep,

doi = "10.1038/pcan.2009.18",

language = "English",

volume = "12",

pages = "296 -- 300",

journal = "Prostate Cancer & Prostatic Diseases",

publisher = "Springer Nature",

}

TY - JOUR

T1 - PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis

AU - Murad, AS

AU - Lewis, SJ

AU - Davey Smith, G

AU - Collin, SM

AU - L, Chen

AU - FC, Hamdy

AU - DE, Neal

AU - Donovan, JL

AU - Martin, RM

PY - 2009/9

Y1 - 2009/9

N2 - Prostaglandin endoperoxidase synthase 2 is a key regulator of inflammation and may play a role in prostate carcinogenesis. The polymorphism, -899G>C (rs20417), alters a transcription factor-binding site and is associated with a reduced risk of colorectal adenoma. We tested the hypothesis that rs20417 may influence prostate cancer risk, using a large case-control study (n(cases)=1608, n(controls)=3058). We found no evidence that rs20417 alters prostate cancer risk (odds ratio (OR(CC & GC v GG)=1.05, 95% confidence interval (CI)=0.91-1.20). A meta-analysis of three studies also found little evidence that rs20417 alters risk (pooled OR(CC & GC v GG)=1.04, 95% CI=0.93-1.17), making it unlikely that rs20417 contributes in any major way to prostate cancer aetiology.

AB - Prostaglandin endoperoxidase synthase 2 is a key regulator of inflammation and may play a role in prostate carcinogenesis. The polymorphism, -899G>C (rs20417), alters a transcription factor-binding site and is associated with a reduced risk of colorectal adenoma. We tested the hypothesis that rs20417 may influence prostate cancer risk, using a large case-control study (n(cases)=1608, n(controls)=3058). We found no evidence that rs20417 alters prostate cancer risk (odds ratio (OR(CC & GC v GG)=1.05, 95% confidence interval (CI)=0.91-1.20). A meta-analysis of three studies also found little evidence that rs20417 alters risk (pooled OR(CC & GC v GG)=1.04, 95% CI=0.93-1.17), making it unlikely that rs20417 contributes in any major way to prostate cancer aetiology.

U2 - 10.1038/pcan.2009.18

DO - 10.1038/pcan.2009.18

M3 - Article (Academic Journal)

C2 - 19488068

VL - 12

SP - 296

EP - 300

JO - Prostate Cancer & Prostatic Diseases

JF - Prostate Cancer & Prostatic Diseases

ER -

PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis

Abstract

UN SDGs

Access to Document

Handle.net

Fingerprint

Cite this